Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 89 | NantCell, Inc.INDUSTRY | 0 | Aug 20, 2024 | clinicaltrials |
| NCT05849246 | The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) | terminated | Phase 2 | 4 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY |
| 1 |
| Aug 20, 2024 |
| clinicaltrials |
| NCT03050554 | SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 2 | Andrew SharabiOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05084859 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 30 | Biosplice Therapeutics, Inc.INDUSTRY | 2 | Aug 9, 2024 | clinicaltrials |
| NCT02798003 | Food Reward in Cachexia Induced by Acute or Chronic Disease | terminated | — | 44 | Maastricht University Medical CenterOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT00998166 | A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy | terminated | Phase 2 | 12 | Columbia UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 37 | PfizerINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT04957602 | Evaluation of a Novel Microfluidic Device to Purify Metastatic Lung Cancer Patients CTC (Circulating Tumoral Cells)(LUTON) | terminated | — | 6 | Hospices Civils de LyonOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT04198818 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors | terminated | Phase 1 / Phase 2 | 37 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jul 19, 2024 | clinicaltrials |
| NCT05583188 | Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC(VIGOR) | terminated | Phase 4 | 5 | Galvanize Therapeutics, Inc.INDUSTRY | 1 | Jul 19, 2024 | clinicaltrials |
| NCT06507891 | A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets | terminated | Phase 1 / Phase 2 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | terminated | Phase 1 | 3 | Hoffmann-La RocheINDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT02954523 | Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations | terminated | Phase 1 / Phase 2 | 10 | Chul KimOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT04822298 | Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer | terminated | Phase 1 | 3 | AmgenINDUSTRY | 3 | Jul 5, 2024 | clinicaltrials |
| NCT02949843 | Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations | terminated | Phase 2 | 19 | Wake Forest University Health SciencesOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT04908956 | Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)(STEREO) | terminated | Phase 2 | 6 | ETOP IBCSG Partners FoundationNETWORK | 8 | Jun 28, 2024 | clinicaltrials |
| NCT04402008 | Study of Poziotinib in Japanese Patients With NSCLC | terminated | Phase 1 / Phase 2 | 42 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05621525 | Phase I Study of the BBP-398 in Patients With Advance Solid Tumors | terminated | Phase 1 | 7 | LianBio LLCINDUSTRY | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03968419 | This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.(CANOPY-N) | terminated | Phase 2 | 88 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 20, 2024 | clinicaltrials |
| NCT04037462 | Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy | terminated | Phase 1 / Phase 2 | 2 | VA Office of Research and DevelopmentFED | 1 | Jun 14, 2024 | clinicaltrials |
| NCT03095612 | Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 41 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 78 | ADC Therapeutics S.A.INDUSTRY | 3 | Jun 13, 2024 | clinicaltrials |
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations | terminated | Phase 1 / Phase 2 | 41 | Turning Point Therapeutics, Inc.INDUSTRY | 2 | Jun 13, 2024 | clinicaltrials |
| NCT02974426 | To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer | terminated | Phase 3 | 132 | Shanghai Chest HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT05435846 | Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation | terminated | Phase 1 | 3 | Collin BlakelyOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT02309892 | A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC | terminated | Phase 1 | 14 | Helix BioPharma CorporationINDUSTRY | 1 | Jun 3, 2024 | clinicaltrials |
| NCT06288646 | Using Infrared Spectroscopy to Analyze Volatile Organic Compounds (VOCs) in the Breath of Patients With Lung Cancer | terminated | — | 12 | Breathe BioMedical IncINDUSTRY | 1 | May 31, 2024 | clinicaltrials |
| NCT02635061 | Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer | terminated | Phase 1 | 17 | CelgeneINDUSTRY | 1 | May 7, 2024 | clinicaltrials |
| NCT05493501 | Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer | terminated | Phase 3 | 8 | EQRx International, Inc.INDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT04476797 | Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC(GRECO-1) | terminated | Phase 1 / Phase 2 | 47 | Galera Therapeutics, Inc.INDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT04211922 | Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib | terminated | Phase 2 | 4 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT05709821 | IMM60 and Pembrolizumab in Melanoma and NSCLC | terminated | Phase 1 / Phase 2 | 1 | iOx TherapeuticsINDUSTRY | 3 | Apr 24, 2024 | clinicaltrials |
| NCT02954991 | Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer | terminated | Phase 2 | 161 | Mirati Therapeutics Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT04772053 | Molecular Disease Characterization Initiative (MDCI) | terminated | Phase 2 | 6 | GlaxoSmithKlineINDUSTRY | 2 | Apr 19, 2024 | clinicaltrials |
| NCT04027946 | LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT02920996 | Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | terminated | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT03472560 | A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) | terminated | Phase 2 | 61 | PfizerINDUSTRY | 8 | Apr 9, 2024 | clinicaltrials |
| NCT03866980 | A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer | terminated | Phase 3 | 164 | AkesoINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT00310232 | Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20) | terminated | Phase 3 | 70 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 86 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04396340 | First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b | terminated | Phase 1 | 31 | Mersana TherapeuticsINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT01953926 | Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations(SUMMIT) | terminated | Phase 2 | 582 | Puma Biotechnology, Inc.INDUSTRY | 13 | Mar 12, 2024 | clinicaltrials |
| NCT04923802 | Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)(MOTIVATION) | terminated | — | 13 | GeneCast Biotechnology Co., Ltd.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT05121948 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | terminated | Phase 1 | 35 | HiberCell, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04816214 | Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy(GEOMETRY-E) | terminated | Phase 3 | 6 | Novartis PharmaceuticalsINDUSTRY | 3 | Mar 5, 2024 | clinicaltrials |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | terminated | Phase 1 / Phase 2 | 11 | NKGen Biotech, Inc.INDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT03257722 | Pembrolizumab + Idelalisib for Lung Cancer Study(PIL) | terminated | Phase 1 / Phase 2 | 4 | Asha NayakOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04491084 | FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy(FLT3) | terminated | Phase 1 / Phase 2 | 5 | Albert Einstein College of MedicineOTHER | 1 | Feb 28, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 20, 2024source: clinicaltrials